Literature DB >> 16473984

Methylphenidate-enhanced antidepressant response to citalopram in the elderly: a double-blind, placebo-controlled pilot trial.

Helen Lavretsky1, Susan Park, Prabha Siddarth, Anand Kumar, Charles F Reynolds.   

Abstract

OBJECTIVE: The authors evaluated the potential of methylphenidate to accelerate and enhance antidepressant response to citalopram in elderly depressed patients.
METHODS: Sixteen outpatients with major depression were treated in a 10-week double-blind trial. Response was defined as a score on the Hamilton Depression Rating Scale (24-item) of less than 10.
RESULTS: An accelerated response was observed by week 3 in five subjects receiving citalopram (CIT)+methylphenidate (MPH) and in none of those receiving CIT+placebo (PBO). Subjects receiving citalopram and methylphenidate showed a significant improvement in depressive symptoms compared with those on citalopram and placebo.
CONCLUSION: Combined treatment with citalopram and methylphenidate appears to be a viable strategy for accelerating and enhancing antidepressant response in elderly depressed patients limited by tolerability and safety.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16473984     DOI: 10.1097/01.JGP.0000192503.10692.9f

Source DB:  PubMed          Journal:  Am J Geriatr Psychiatry        ISSN: 1064-7481            Impact factor:   4.105


  18 in total

1.  Genomic predictors of remission to antidepressant treatment in geriatric depression using genome-wide expression analyses: a pilot study.

Authors:  Harris A Eyre; Ascia Eskin; Stanley F Nelson; Natalie M St Cyr; Prabha Siddarth; Bernhard T Baune; Helen Lavretsky
Journal:  Int J Geriatr Psychiatry       Date:  2015-10-15       Impact factor: 3.485

Review 2.  Methylphenidate for the treatment of depressive symptoms, including fatigue and apathy, in medically ill older adults and terminally ill adults.

Authors:  Susan E Hardy
Journal:  Am J Geriatr Pharmacother       Date:  2009-02

Review 3.  Strategies to enhance the therapeutic efficacy of antidepressants: targeting residual symptoms.

Authors:  Benji T Kurian; Tracy L Greer; Madhukar H Trivedi
Journal:  Expert Rev Neurother       Date:  2009-07       Impact factor: 4.618

Review 4.  Defining and measuring functional recovery from depression.

Authors:  Tracy L Greer; Benji T Kurian; Madhukar H Trivedi
Journal:  CNS Drugs       Date:  2010-04       Impact factor: 5.749

Review 5.  Use of antidepressants in late-life depression.

Authors:  Tarek K Rajji; Benoit H Mulsant; Francis E Lotrich; Cynthia Lokker; Charles F Reynolds
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

6.  The role of methylphenidate in the treatment of catatonia.

Authors:  Edith Sciberras; Joseph Cassar
Journal:  Psychopharmacology (Berl)       Date:  2019-11-09       Impact factor: 4.530

7.  Pharmacological Augmentation in Unipolar Depression: A Guide to the Guidelines.

Authors:  Rachael W Taylor; Lindsey Marwood; Emanuella Oprea; Valeria DeAngel; Sarah Mather; Beatrice Valentini; Roland Zahn; Allan H Young; Anthony J Cleare
Journal:  Int J Neuropsychopharmacol       Date:  2020-12-03       Impact factor: 5.176

Review 8.  Aripiprazole as adjunctive therapy for patients with major depressive disorder: overview and implications of clinical trial data.

Authors:  Chi-Un Pae; Andy Forbes; Ashwin A Patkar
Journal:  CNS Drugs       Date:  2011-02       Impact factor: 5.749

Review 9.  Treatment of depression in patients with congestive heart failure.

Authors:  Peter A Shapiro
Journal:  Heart Fail Rev       Date:  2007-10-23       Impact factor: 4.214

10.  Design and synthesis of 4-heteroaryl 1,2,3,4-tetrahydroisoquinolines as triple reuptake inhibitors.

Authors:  Shuang Liu; Congxiang Zha; Kassoum Nacro; Min Hu; Wenge Cui; Yuh-Lin Yang; Ulhas Bhatt; Aruna Sambandam; Matthew Isherwood; Larry Yet; Michael T Herr; Sarah Ebeltoft; Carla Hassler; Linda Fleming; Anthony D Pechulis; Anne Payen-Fornicola; Nicholas Holman; Dennis Milanowski; Ian Cotterill; Vadim Mozhaev; Yuri Khmelnitsky; Peter R Guzzo; Bruce J Sargent; Bruce F Molino; Richard Olson; Dalton King; Snjezana Lelas; Yu-Wen Li; Kim Johnson; Thaddeus Molski; Anitra Orie; Alicia Ng; Roy Haskell; Wendy Clarke; Robert Bertekap; Jonathan O'Connell; Nicholas Lodge; Michael Sinz; Stephen Adams; Robert Zaczek; John E Macor
Journal:  ACS Med Chem Lett       Date:  2014-05-13       Impact factor: 4.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.